Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor
MetadataShow full item record
The amyloid- (A) peptide is neurotoxic and associated with the pathology of Alzheimer's disease (AD). We investigated the effect of A peptides on insulin binding to the insulin receptor because it is known that (1) A and insulin are both amyloidogenic peptides sharing a common sequence recognition motif, (2) A and insulin are substrates for the same insulin degrading enzyme, and (3) impaired glucose metabolism is a characteristic event in the pathology of AD. We discovered that A1-40 and A1-42, the main physiological forms, reduced insulin binding and receptor autophosphorylation. The reduction in binding was caused by a decrease in the affinity of insulin binding to the insulin receptor. This reduction was independent of the receptor concentration. The reverse, control peptide A40-1 did not reduce insulin binding or insulin receptor autophosphorylation. These results demonstrate that A is a direct competitive inhibitor of insulin binding and action. We speculate that the increased levels of A in Alzheimer's disease may be linked to the associated insulin resistance that has been observed previously in this disease.
Copyright 2002 Society of Neuroscience
Please refer to the publisher for the definitive published version.
Showing items related by title, author, creator and subject.
Deleo, Domenica (1994)Prior to the commencement of this study in 1990, a number of reports had appeared in the literature describing the importance of insulin action during lactation in mammals (see Chapter 1). These studies investigated the ...
Elaskalani, O.; Khan, I.; Morici, M.; Matthysen, C.; Sabale, M.; Martins, R.; Verdile, G.; Metharom, Pat (2017)© 2017 Taylor & Francis The effects of the Alzheimer’s disease (AD)-associated Amyloid-ß (Aß) peptides on platelet aggregation have been previously assessed, but most of these studies focused on Aß40 species. It also ...
The potential of a cross-linked human serum albumin dimer in diabetic rats as an augmenting agent for antidiabetic drugsTaguchi, K.; Chuang, Victor; Yamasaki, K.; Kawai, K.; Maruyama, T.; Komatsu, T.; Otagiri, Masaki (2015)Purpose: The half-life of insulin analogs and glucagon like peptide-1 (GLP-1) receptor agonist is prolonged through binding to albumin, but this may not occur in hypoalbuminemic diabetic patients with protein leaking from ...